Harvey P D, Davidson M, White L, Keefe R S, Hirschowitz J, Mohs R C, Davis K L
Department of Psychiatry, Mt. Sinai School of Medicine, New York, NY 10029, USA.
Biol Psychiatry. 1996 Oct 15;40(8):755-60. doi: 10.1016/0006-3223(95)00486-6.
There has been little investigation of the effect of neuroleptic medication on the structure of symptoms in schizophrenia. In this study, 135 male schizophrenic patients were rated with the Brief Psychiatric Rating Scale (BPRS) after 4 weeks of treatment with typical neuroleptic medication and after 2 weeks free of neuroleptics, with the order of assessment varying across patients. Confirmatory factor analyses (CFA) found that there were no differences in symptom structure across medication status and no differences in the structure of symptoms in treatment responders and nonresponders. The typical 5-factor BPRS model fit the data poorly and the fit improved considerably through deletion of items measuring symptoms not associated with schizophrenia, suggesting that some of the symptoms that contribute to a total BPRS score may be adding primarily error variance. Although the sample size in this study is limited, the results suggest that using total BPRS scores to measure severity of schizophrenic symptoms should be reconsidered.
关于抗精神病药物对精神分裂症症状结构的影响,此前鲜有研究。在本研究中,135名男性精神分裂症患者在接受典型抗精神病药物治疗4周后以及停用抗精神病药物2周后,使用简明精神病评定量表(BPRS)进行评分,评估顺序因患者而异。验证性因素分析(CFA)发现,不同用药状态下的症状结构没有差异,治疗反应者和无反应者的症状结构也没有差异。典型的5因素BPRS模型对数据的拟合较差,通过删除测量与精神分裂症无关症状的条目,拟合有了显著改善,这表明一些对BPRS总分有贡献的症状可能主要增加了误差方差。尽管本研究的样本量有限,但结果表明,使用BPRS总分来衡量精神分裂症症状的严重程度值得重新考虑。